|
1
|
Clark JI, Hofmeister C, Choudhury A, et
al: Phase II evaluation of paclitaxel in combination with
carboplatin in advanced head and neck carcinoma. Cancer.
92:2334–2340. 2001.
|
|
2
|
Hoffman HT, Porter K, Karnell LH, et al:
Laryngeal cancer in the United States: changes in demographics,
patterns of care, and survival. Laryngoscope. 116(Suppl 111):
S1–S13. 2006.
|
|
3
|
Ma J, Lu S, Yu L, et al: FaDu cell
characteristics induced by multidrug resistance. Oncol Rep.
26:1189–1195. 2011.
|
|
4
|
Baeuerle PA and Gires O: EpCAM (CD326)
finding its role in cancer. Br J Cancer. 96:417–423. 2007.
|
|
5
|
Schnell U, Cirulli V and Giepmans BN:
EpCAM: structure and function in health and disease. Biochim
Biophys Acta. 1828:1989–2001. 2013.
|
|
6
|
Went P, Vasei M, Bubendorf L, et al:
Frequent high-level expression of the immunotherapeutic target
Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer.
94:128–135. 2006.
|
|
7
|
Osta WA, Chen Y, Mikhitarian K, et al:
EpCAM is overexpressed in breast cancer and is a potential target
for breast cancer gene therapy. Cancer Res. 64:5818–5824. 2004.
|
|
8
|
Flatmark K, Borgen E, Nesland JM, et al:
Disseminated tumour cells as a prognostic biomarker in colorectal
cancer. Br J Cancer. 104:1434–1439. 2011.
|
|
9
|
Ni J, Cozzi PJ, Duan W, et al: Role of the
EpCAM (CD326) in prostate cancer metastasis and progression. Cancer
Metastasis Rev. 31:779–791. 2012.
|
|
10
|
Ji J, Yamashita T, Budhu A, et al:
Identification of microRNA-181 by genome-wide screening as a
critical player in EpCAM-positive hepatic cancer stem cells.
Hepatology. 50:472–480. 2009.
|
|
11
|
Pauli C, Münz M, Kieu C, et al:
Tumor-specific glycosylation of the carcinoma-associated epithelial
cell adhesion molecule EpCAM in head and neck carcinomas. Cancer
Lett. 193:25–32. 2003.
|
|
12
|
Litvinov SV, Velders MP, Bakker HA,
Fleuren GJ and Warnaar SO: Ep-CAM: a human epithelial antigen is a
homophilic cell-cell adhesion molecule. J Cell Biol. 125:437–446.
1994.
|
|
13
|
Balzar M, Prins FA, Bakker HA, Fleuren GJ,
Warnaar SO and Litvinov SV: The structural analysis of adhesions
mediated by Ep-CAM. Exp Cell Res. 246:108–121. 1999.
|
|
14
|
Winter MJ, Nagelkerken B, Mertens AE,
Rees-Bakker HA, Briaire-de Bruijn IH and Litvinov SV: Expression of
Ep-CAM shifts the state of cadherin-mediated adhesions from strong
to weak. Exp Cell Res. 285:50–58. 2003.
|
|
15
|
Maetzel D, Denzel S, Mack B, et al:
Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell
Biol. 11:162–171. 2009.
|
|
16
|
Visvader JE and Lindeman GJ: Cancer stem
cells in solid tumours: accumulating evidence and unresolved
questions. Nat Rev Cancer. 8:755–768. 2008.
|
|
17
|
Gires O, Klein CA and Baeuerle PA: On the
abundance of EpCAM on cancer stem cells. Nat Rev Cancer.
9:1432009.
|
|
18
|
van der Gun BT, Melchers LJ, Ruiters MH,
de Leij LF, McLaughlin PM and Rots MG: EpCAM in carcinogenesis: the
good, the bad or the ugly. Carcinogenesis. 31:1913–1921. 2010.
|
|
19
|
Kroepil F, Dulian A, Vallböhmer D, et al:
High EpCAM expression is linked to proliferation and lauren
classification in gastric cancer. BMC Res Notes. 6:2532013.
|
|
20
|
Yanamoto S, Kawasaki G, Yoshitomi I,
Iwamoto T, Hirata K and Mizuno A: Clinicopathologic significance of
EpCAM expression in squamous cell carcinoma of the tongue and its
possibility as a potential target for tongue cancer gene therapy.
Oral Oncol. 43:869–877. 2007.
|
|
21
|
Litvinov SV, Bakker HA, Gourevitch MM,
Velders MP and Warnaar SO: Evidence for a role of the epithelial
glycoprotein 40 (Ep-CAM) in epithelial cell-cell adhesion. Cell
Adhes Commun. 2:417–428. 1994.
|
|
22
|
Dufour S, Mège RM and Thiery JP:
α-catenin, vinculin, and F-actin in strengthening E-cadherin
cell-cell adhesions and mechanosensing. Cell Adh Migr. 7:345–350.
2013.
|
|
23
|
Chaves-Pérez A, Mack B, Maetzel D, et al:
EpCAM regulates cell cycle progression via control of cyclin D1
expression. Oncogene. 32:641–650. 2013.
|
